Advanced search
Publication Cover
Journal of Asthma and Allergy Volume 15, 2022 - Issue
Submit an article Journal homepage
120
Views
0
CrossRef citations to date
0
Altmetric
Research Letter

Improvement in Lung Function with Dupilumab Does Not Predict Its Effects on Reducing Asthma Exacerbation

Nicola A Hanania1 Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, TX, USACorrespondence[email protected]
View further author information
,
Jorge F Maspero2 Fundación CIDEA, Buenos Aires, ArgentinaView further author information
,
David M G Halpin3 University of Exeter Medical School, College of Medicine and Health, University of Exeter, Exeter, UKORCID Iconhttps://orcid.org/0000-0003-2009-4406View further author information
ORCID Icon,
David J Jackson4 School of Immunology and Microbial Sciences, King’s College London, London, UK;5 Guy’s Severe Asthma Centre, Guy’s and St Thomas’ NHS Foundation Trust, London, UKView further author information
,
Reynold A Panettieri6 Child Health Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ, USAORCID Iconhttps://orcid.org/0000-0003-0834-4636View further author information
ORCID Icon,
Mario Castro7 University of Kansas School of Medicine, Kansas City, KS, USAView further author information
,
Christian Domingo8 Pulmonary Service, Corporació Sanitària Parc Taulí, Sabadell, Autonomous University of Barcelona, Barcelona, SpainView further author information
,
Nadia Daizadeh9 Sanofi, Cambridge, MA, USAView further author information
,
Rebecca Gall10 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USAView further author information
,
Juby A Jacob-Nara11 Sanofi, Bridgewater, NJ, USAView further author information
,
Benjamin Ortiz10 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USAView further author information
,
Michel Djandji9 Sanofi, Cambridge, MA, USAView further author information
,
Paul J Rowe11 Sanofi, Bridgewater, NJ, USAView further author information
&
Yamo Deniz10 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USAView further author information
 show all
Pages 851-854 | Published online: 28 Jun 2022

Figures & data

Figure 1 Adjusted annualized rate of severe asthma exacerbations in patients with and without clinically meaningful improvements in pre-bronchodilator FEV1 during the QUEST study (patients with uncontrolled, moderate-to-severe asthma and a type 2 phenotype) were analyzed using a negative binomial regression model. ***p < 0.001 vs placebo.

Abbreviations: BD, bronchodilator; CI, confidence interval; FEV1, forced expiratory volume in 1 second.
Figure 1 Adjusted annualized rate of severe asthma exacerbations in patients with and without clinically meaningful improvements in pre-bronchodilator FEV1 during the QUEST study (patients with uncontrolled, moderate-to-severe asthma and a type 2 phenotype) were analyzed using a negative binomial regression model. ***p < 0.001 vs placebo.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.